Literature DB >> 26993029

Statins reduce spirochetal burden and modulate immune responses in the C3H/HeN mouse model of Lyme disease.

Tricia A Van Laar1, Camaron Hole1, S L Rajasekhar Karna1, Christine L Miller1, Robert Reddick2, Floyd L Wormley1, J Seshu3.   

Abstract

Lyme disease (LD) is a systemic disorder caused by Borrelia burgdorferi. Lyme spirochetes encode for a functional 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMGR EC 1.1.1.88) serving as a rate limiting enzyme of the mevalonate pathway that contribute to components critical for cell wall biogenesis. Statins have been shown to inhibit B. burgdorferi in vitro. Using a mouse model of Lyme disease, we found that statins contribute to reducing bacterial burden and altering the murine immune response to favor clearance of spirochetes.
Copyright © 2016 Institut Pasteur. All rights reserved.

Entities:  

Keywords:  Borrelia burgdorferi; Cell wall biogenesis; Lyme disease; Statins

Mesh：

Substances：

Year:  2016        PMID： 26993029      PMCID： PMC4975942          DOI： 10.1016/j.micinf.2016.03.004

Source DB:  PubMed          Journal:  Microbes Infect        ISSN： 1286-4579            Impact factor:   2.700


  25 in total

1.  Induction of pro- and anti-inflammatory cytokines by Borrelia burgdorferi lipoproteins in monocytes is mediated by CD14.

Authors:  G H Giambartolomei; V A Dennis; B L Lasater; M T Philipp
Journal:  Infect Immun       Date:  1999-01       Impact factor: 3.441

Review 2.  Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors.

Authors:  B A Hamelin; J Turgeon
Journal:  Trends Pharmacol Sci       Date:  1998-01       Impact factor: 14.819

Review 3.  The biological and social phenomenon of Lyme disease.

Authors:  A G Barbour; D Fish
Journal:  Science       Date:  1993-06-11       Impact factor: 47.728

4.  Attachment of Borrelia burgdorferi within Ixodes scapularis mediated by outer surface protein A.

Authors:  U Pal; A M de Silva; R R Montgomery; D Fish; J Anguita; J F Anderson; Y Lobet; E Fikrig
Journal:  J Clin Invest       Date:  2000-08       Impact factor: 14.808

5.  The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease.

Authors:  Sawsan Youssef; Olaf Stüve; Juan C Patarroyo; Pedro J Ruiz; Jennifer L Radosevich; Eun Mi Hur; Manuel Bravo; Dennis J Mitchell; Raymond A Sobel; Lawrence Steinman; Scott S Zamvil
Journal:  Nature       Date:  2002-11-07       Impact factor: 49.962

6.  Surveillance for Lyme disease--United States, 1992-1998.

Authors:  K A Orloski; E B Hayes; G L Campbell; D T Dennis
Journal:  MMWR CDC Surveill Summ       Date:  2000-04-28

7.  Sequence comparisons reveal two classes of 3-hydroxy-3-methylglutaryl coenzyme A reductase.

Authors:  D A Bochar; C V Stauffacher; V W Rodwell
Journal:  Mol Genet Metab       Date:  1999-02       Impact factor: 4.797

8.  Lyme borreliosis: detecting the great imitator.

Authors:  N Burdash; J Fernandes
Journal:  J Am Osteopath Assoc       Date:  1991-06

9.  Acylated cholesteryl galactosides are specific antigens of borrelia causing lyme disease and frequently induce antibodies in late stages of disease.

Authors:  Gunthard Stübs; Volker Fingerle; Bettina Wilske; Ulf B Göbel; Ulrich Zähringer; Ralf R Schumann; Nicolas W J Schröder
Journal:  J Biol Chem       Date:  2009-03-23       Impact factor: 5.157

10.  ELISA-based measurement of antibody responses and PCR-based detection profiles can distinguish between active infection and early clearance of Borrelia burgdorferi.

Authors:  John J Lazarus; Akisha L McCarter; Kari Neifer-Sadhwani; R Mark Wooten
Journal:  Clin Dev Immunol       Date:  2011-10-26
View more
  5 in total

1.  Borrelia Host Adaptation Protein (BadP) Is Required for the Colonization of a Mammalian Host by the Agent of Lyme Disease.

Authors:  Trever C Smith; Sarah M Helm; Yue Chen; Ying-Han Lin; S L Rajasekhar Karna; J Seshu
Journal:  Infect Immun       Date:  2018-06-21       Impact factor: 3.441

2.  Short-Chain Fatty Acids Alter Metabolic and Virulence Attributes of Borrelia burgdorferi.

Authors:  Ying-Han Lin; Yue Chen; Trever C Smith; S L Rajasekhar Karna; J Seshu
Journal:  Infect Immun       Date:  2018-08-22       Impact factor: 3.441

3.  Effect of Statin Use on the Clinical Manifestations, Laboratory Test Results and Outcome of Lyme Neuroborreliosis.

Authors:  Katarina Ogrinc; Andrej Kastrin; Stanka Lotrič-Furlan; Petra Bogovič; Tereza Rojko; Tjaša Cerar-Kišek; Eva Ružić-Sabljić; Gary P Wormser; Franc Strle
Journal:  J Clin Med       Date:  2020-09-16       Impact factor: 4.241

4.  Association between statin use and clinical course, microbiologic characteristics, and long-term outcome of early Lyme borreliosis. A post hoc analysis of prospective clinical trials of adult patients with erythema migrans.

Authors:  Daša Stupica; Fajko F Bajrović; Rok Blagus; Tjaša Cerar Kišek; Stefan Collinet-Adler; Eva Ružić-Sabljić; Maša Velušček
Journal:  PLoS One       Date:  2021-12-16       Impact factor: 3.240

5.  Specific composition of polyphenolic compounds with fatty acids as an approach in helping to reduce spirochete burden in Lyme disease: in vivo and human observational study.

Authors:  Anna Goc; Gebhard Gehring; Hartmut Baltin; Aleksandra Niedzwiecki; Matthias Rath
Journal:  Ther Adv Chronic Dis       Date:  2020-05-24       Impact factor: 5.091
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.